4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
ARCT - Arcturus Therapeutics Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$30.50
DETAILS
HIGH:
$41.00
LOW:
$20.00
MEDIAN:
$30.50
CONSENSUS:
$30.50
UPSIDE:
177.78%
Stock News
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus' m.
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program
Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2 interim data, normalizing glutamine and ammonia levels, and is designated Orphan Drug, Fast Track, and Rare Pediatric Disease by the FDA. The upcoming Sep. 23 presentation on ARCT-810 could be stock-moving, but small trial sizes mean results should be viewed as hypothesis-generating.
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics Holdings Inc. (the âCompanyâ, âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus' mRNA liver therapeutics pl.
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
56,895 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Bought by Hsbc Holdings PLC
Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 56,895 shares of the biotechnology company's stock, valued at approximately $394,000. Hsbc Holdings PLC
BlackRock Inc. Invests $17.57 Million in Arcturus Therapeutics Holdings Inc. $ARCT
BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,614,012 shares of the biotechnology company's stock, valued at approximately $17,566,000. BlackRock Inc. owned 9.20% of Arcturus Therapeutics
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat September 8, 2026 (2:15 p.m. ET) Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat September 9.
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings.
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Zenas
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has
Price Targets
Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG
$20.00
(was $13.30)
Thomas Shrader
·
BTIG
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
$41.00
(was $16.23)
Roth Capital
'2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler
$25.00
(was $7.42)
Yasmeen Rahimi
·
Piper Sandler
Arcturus Therapeutics initiated with a Buy at Roth Capital
$20.00
(was $7.59)
Roth Capital
Arcturus Therapeutics price target lowered to $54 from $63 at Leerink
$54.00
(was $18.51)
Lili Nsongo
·
Leerink Partners
Arcturus Therapeutics initiated with an Outperform at Scotiabank
$32.00
(was $11.82)
Greg Harrison
·
Scotiabank
BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
$48.00
(was $14.55)
Thomas Shrader
·
BTIG
Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity
$74.00
(was $3.02)
Whitney Ijem
·
Canaccord Genuity
Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord
$72.00
(was $3.20)
Whitney Ijem
·
Canaccord Genuity
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
$60.00
(was $3.38)
Ed Arce
·
H.C. Wainwright
Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT)
$140.00
(was $5.64)
Yasmeen Rahimi
·
Piper Sandler
Arcturus Therapeutics price target lowered to $86 from $87 at Canaccord
$86.00
(was $3.83)
Whitney Ijem
·
Canaccord Genuity
Laidlaw Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
$79.00
(was $4.83)
Yale Jen
·
Laidlaw
Barclays Upgrades Arcturus Therapeutics (ARCT) to Equalweight
$25.00
(was $21.69)
Gena Wang
·
Barclays
Goldman Sachs Maintains Sell on Arcturus Therapeutics, Lowers Price Target to $14
$14.00
(was $13.55)
Goldman Sachs
UPDATE: Arcturus Therapeutics (ARCT) PT Raised to $30 at Goldman Sachs (CORRECTION)
$30.00
(was $36.23)
Madhu Kumar
·
Goldman Sachs